HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M600040-JLR200v1 47/6/1307    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, J. Articles by Jiang, X.-C. Search for Related Content PubMed PubMed Citation Articles by Dong, J. Articles by Jiang, X.-C. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 47, 1307-1314, June 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology

Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice

Jibin Dong^1,*, Jin Liu^1,, Bin Lou^*, Zhiqiang Li, Xun Ye, Manping Wu^2,* and Xian-Cheng Jiang^2,

^* School of Pharmacy, Fudan University, Shanghai, People's Republic of China
Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY
Department of Pharmacology, College of Basic Medical Sciences, Shanghai Jiaotong University, Shanghai, People's Republic of China

Published, JLR Papers in Press, February 28, 2006.

¹ J. Dong and J. Liu contributed equally to this report.

² To whom correspondence should be addressed. e-mail: mpwu{at}shmu.edu.cn (M.W.); xjiang{at}downstate.edu (X-C.J.)

Sphingomyelin synthase 1 (SMS1) and SMS2 are two isoforms of SMS, the last enzyme for sphingomyelin (SM) biosynthesis. To evaluate the role of SMS in vivo in terms of plasma lipoprotein metabolism, we generated recombinant adenovirus vectors containing human SMS1 cDNA (AdV-SMS1), SMS2 cDNA (AdV-SMS2), or the reporter LacZ cDNA (AdV-LacZ) as a control. On day 7 after intravenous infusion of 2 x 10¹¹ particles of both AdV-SMS1 and AdV-SMS2 into mice, liver SMS1 and SMS2 mRNA levels as well as SMS activity were significantly increased (2.5-, 2.7-, 2.1-, and 2.3-fold, respectively; P < 0.001). Lipoprotein analysis indicated that AdV-SMS1 and AdV-SMS2 treatment caused no changes of total SM and cholesterol levels but significantly decreased HDL-SM and HDL-cholesterol (42% and 38%, and 27% and 25%, respectively; P < 0.05). It also significantly increased non-HDL-SM and non-HDL-cholesterol levels (50% and 35%, and 64% and 61%, respectively; P < 0.05) compared with AdV-LacZ controls. SDS-PAGE showed a significant increase in apolipoprotein B (apoB; P < 0.01) but no changes in apoA-I levels. Moreover, we found that non-HDL from both AdV-SMS1- and AdV-SMS2-treated mice was significantly aggregated after treatment with a mammalian sphingomyelinase, whereas lipoproteins from control animals did not aggregate. To investigate the mechanism of HDL changes, we measured liver scavenger receptor class B type I (SR-BI) levels by Western blot. We found that AdV-SMS1 and AdV-SMS2 mouse liver homogenates contained 50% and 55% higher SR-BI levels than in controls, whereas no change was observed in hepatic ABCA1 levels. An HDL turnover study revealed an increase of plasma clearance rates for [³H]cholesteryl oleyl ether-HDL but not for [¹²⁵I]HDL in both AdV-SMS1 and AdV-SMS2 mice compared with controls. In conclusion, adenovirus-mediated SMS1 and SMS2 overexpression increased lipoprotein atherogenic potential. Such an effect may contribute to the increased plasma SM levels observed in animal models of atherosclerosis and in human patients with coronary artery disease.

Supplementary key words lipoprotein • atherosclerosis • sphingolipid

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Schafer, A. Parlesak, J. Eckoldt, C. Bode, J. C. Bode, W. Marz, and K. Winkler Beyond HDL-cholesterol increase: phospholipid enrichment and shift from HDL3 to HDL2 in alcohol consumers J. Lipid Res., July 1, 2007; 48(7): 1550 - 1558. [Abstract] [Full Text] [PDF]